S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Metacrine Stock Forecast, Price & News

-0.04 (-2.96%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
389,928 shs
Average Volume
481,202 shs
Market Capitalization
$35.78 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MTCR News and Ratings via Email

Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter.

Metacrine logo

About Metacrine

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$1.73 per share


Net Income
$-37.30 million
Pretax Margin




Free Float
Market Cap
$35.78 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.26 out of 5 stars

Medical Sector

315th out of 1,391 stocks

Pharmaceutical Preparations Industry

138th out of 669 stocks

Analyst Opinion: 3.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -

Metacrine (NASDAQ:MTCR) Frequently Asked Questions

Is Metacrine a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Metacrine in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Metacrine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MTCR, but not buy additional shares or sell existing shares.
View analyst ratings for Metacrine
or view top-rated stocks.

Are investors shorting Metacrine?

Metacrine saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 368,200 shares, a decline of 23.6% from the October 31st total of 481,800 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.9% of the company's stock are sold short.
View Metacrine's Short Interest

When is Metacrine's next earnings date?

Metacrine is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Metacrine

How were Metacrine's earnings last quarter?

Metacrine, Inc. (NASDAQ:MTCR) issued its earnings results on Thursday, May, 13th. The company reported ($0.57) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.06.
View Metacrine's earnings history

What price target have analysts set for MTCR?

4 brokers have issued twelve-month price objectives for Metacrine's stock. Their forecasts range from $2.00 to $19.00. On average, they anticipate Metacrine's stock price to reach $9.63 in the next twelve months. This suggests a possible upside of 634.7% from the stock's current price.
View analysts' price targets for Metacrine
or view top-rated stocks among Wall Street analysts.

Who are Metacrine's key executives?

Metacrine's management team includes the following people:
  • Dr. Preston S. Klassen, Pres, CEO & Director (Age 52, Pay $522.51k) (LinkedIn Profile)
  • Ms. Patricia M. Millican, Chief Financial Officer (Age 48, Pay $496.09k)
  • Ms. Catherine C. Lee, Exec. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $383.32k)
  • Ms. Patricia Millican, Chief Financial Officer (Age 48)
  • Ms. Theresa Lowry, VP of HR
  • Dr. Hubert C. Chen, Chief Medical Officer (Age 52) (LinkedIn Profile)

What other stocks do shareholders of Metacrine own?

When did Metacrine IPO?

(MTCR) raised $84 million in an initial public offering on Wednesday, September 16th 2020. The company issued 6,500,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Metacrine's stock symbol?

Metacrine trades on the NASDAQ under the ticker symbol "MTCR."

Who are Metacrine's major shareholders?

Metacrine's stock is owned by a number of institutional and retail investors. Top institutional investors include Prosight Management LP (4.32%), Franklin Resources Inc. (1.37%), Renaissance Technologies LLC (1.07%), ArrowMark Colorado Holdings LLC (1.06%), Millennium Management LLC (0.71%) and BlackRock Inc. (0.52%). Company insiders that own Metacrine stock include Alexandria Venture Investments, Global Strategic Fund Venbio, Hubert C Chen and Preston Klassen.
View institutional ownership trends for Metacrine

Which institutional investors are selling Metacrine stock?

MTCR stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., ArrowMark Colorado Holdings LLC, Millennium Management LLC, Goldman Sachs Group Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Metacrine
or view top insider-selling stocks.

Which institutional investors are buying Metacrine stock?

MTCR stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Renaissance Technologies LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Belvedere Trading LLC, BlackRock Inc., and Citadel Advisors LLC. Company insiders that have bought Metacrine stock in the last two years include Alexandria Venture Investments, Hubert C Chen, and Preston Klassen.
View insider buying and selling activity for Metacrine
or or view top insider-buying stocks.

How do I buy shares of Metacrine?

Shares of MTCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Metacrine's stock price today?

One share of MTCR stock can currently be purchased for approximately $1.31.

How much money does Metacrine make?

Metacrine has a market capitalization of $35.78 million.

How many employees does Metacrine have?

Metacrine employs 35 workers across the globe.

What is Metacrine's official website?

The official website for Metacrine is www.metacrine.com.

Where are Metacrine's headquarters?

How can I contact Metacrine?

Metacrine's mailing address is 3985 SORRENTO VALLEY BLVD. SUITE C, SAN DIEGO CA, 92121. The company can be reached via phone at 858-369-7800 or via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.